The most recent follow-up of nine RF2 patients, among the earliest patients implanted in the VBLOC-RF2 trial, showed an excess weight loss (EWL) of 29.5% at nine months of VBLOC therapy. The most recent results for the prior follow-up periods demonstrate an EWL of 10.2% in 32 RF2 patients at one month, an EWL of 17.5% in 26 RF2 patients at three months and an EWL of 22.1% in 21 RF2 patients at six months of VBLOC therapy.
Mark Knudson, president and CEO of EnteroMedics, said: “We are encouraged by these interim weight loss data and the safety profile of our Maestro RF2 System. The results continue to support VBLOC therapy as a meaningful choice for physicians and their patients seeking sustainable weight loss.”